KOSDAQBiotech & Pharma314930

Biodyne

₩5,160▼ 1.15%2026-11-18 close
Market Cap
₩153.6B
Turnover
₩300M
Volume
50K
Shares out.
29.8M
PER
—
PBR
3.9×
EPS
-₩5
Dividend Yield
0.00%

PER, EPS, PBR and BPS are calculated in-house from the last 4 quarters (2025Q4–2026Q3) · Dividend yield is based on ₩0 per share · Prices as of the 2026-11-18 close

01

Report overview

Royalty-Driven Turnaround Meets Quarterly Losses

Biodyne is a liquid-based cytology diagnostics company whose growth depends on a long-term technology transfer and supply deal with Roche, and it has recorded an operating loss in each quarter from Q1 2026 through Q3 2026 after returning to an annual operating profit in FY2025.

  1. 1

    FY2025 revenue rose 33.3% year on year to KRW 7.03 billion, and operating profit turned positive at KRW 652 million.

  2. 2

    Q3 2026 revenue was KRW 701 million, down 18.4% from the same quarter a year earlier, while the operating loss of KRW 542 million was smaller than in the prior quarter.

  3. 3

    The Q3 2026 net loss attributable to controlling shareholders widened to KRW 1.38 billion, larger than the operating loss in the same quarter.

  4. 4

    Consumable LBC diagnostic kits account for 89.5% of sales, and overseas distributors account for 80.6% of revenue.

  5. 5

    Dependence on a single partner, Roche, and undisclosed contract economics are the key variables for the long-term growth path.

02

Business structure

Biodyne was founded in 1999, came under the leadership of CEO Im Wook-bin in 2009, and listed on KOSDAQ in March 2021.

Its core business is developing, manufacturing and selling LBC diagnostic reagent kits and LBC equipment, mainly for cervical cancer testing, built on its Blowing technology that spreads cells evenly without altering them.

Sales in 2025 were split as follows: LBC diagnostic reagent kits 89.5% (KRW 6.29 billion), LBC equipment 5.3% (KRW 381 million) and other 5.2% (KRW 370 million).

Under a razor-and-blade model, the company supplies equipment to screening centers and then keeps selling consumables such as vials and filters, so consumable sales recur.

Overseas distributors generated 80.6% of sales (KRW 5.66 billion), making export dependence high, while domestic direct and indirect sales accounted for 14.2%.

Roche, the world's largest in vitro diagnostics company, is commercializing equipment and kits using the Blowing technology under a 20-year contract signed in 2019 that renews automatically.

Royalties are linked to the number of tests performed, and past press reports put the royalty rate in the low double-digit percent of sales. Sources differ on the timing of the contract: one securities report describes six years of technology validation starting in 2019 followed by a final agreement in 2022.

Competing products include the filter-based ThinPrep and the sedimentation-based BD SurePath, and Biodyne differentiates through its blowing method. Growth depends heavily on one partner, Roche, and contract values for supply and royalties are confidential, which limits outside visibility.

03

Earnings trend

Quarterly revenue · Operating profit
RevenueOperating profit
Annual revenue · Operating profit
RevenueOperating profit
Quarterly results · Last 5 quarters
QuarterRevenueOperating profitOp. margin
2025Q3₩900M-₩400M−44.6%
2025Q4———
2026Q1₩900M-₩400M−46.5%
2026Q2₩600M-₩700M−115.9%
2026Q3₩700M-₩500M−77.3%
Annual results
YearRevenueOperating profitNet income (parent)Op. marginROEDebt-to-equity
2022₩12.2B₩6.7B₩5.6B54.7%12.7%2.8%
2023₩4.1B-₩2.1B-₩1B−50.2%−2.3%1.4%
2024₩5.3B-₩1.7B₩10,770,170−32.8%0.0%2.7%
2025₩7B₩700M₩900M9.3%1.9%2.0%

Consolidated basis (financial statements including subsidiaries) · Final figures from DART filings · Net income attributable to owners of the parent · Data as of 2026-11-16

04

Earnings analysis

Revenue fell from KRW 12.2 billion in 2022 to KRW 4.09 billion in 2023, down 66.5% year on year, then rose 28.9% to KRW 5.27 billion in 2024 and 33.3% to KRW 7.03 billion in 2025, two consecutive years of growth.

The 2022 peak depended heavily on milestone income: the 2024 Q1 quarterly report shows KRW 7.66 billion of milestone receipts and KRW 4.55 billion of product sales in 2022, so more than half of that year's revenue was non-recurring.

Revenue declined when the milestone receipts were absent in 2023, and the KRW 6.68 billion operating profit in 2022 (operating margin 54.7%) should be read in that context. The company posted an operating loss of KRW 2.05 billion in 2023, a swing from profit, with an operating margin of -50.2%.

The 2024 operating loss narrowed to KRW 1.73 billion (margin -32.8%), while net profit attributable to controlling shareholders turned positive at KRW 10.77 million, pointing to non-operating items that the annual report should clarify.

In 2025 operating profit returned to KRW 652 million (margin 9.3%), and net profit attributable to controlling shareholders of KRW 852 million rose 7,807.0%.

At the end of 2025 total equity stood at KRW 44.1 billion, all attributable to controlling shareholders, with total liabilities of KRW 871 million and a debt ratio of 2.0%.

Quarterly results show the recent pattern: Q3 2025 operating loss of KRW 383 million, Q1 2026 operating loss of KRW 403 million, Q2 2026 operating loss of KRW 681 million on revenue of KRW 587 million, and Q3 2026 operating loss of KRW 542 million on revenue of KRW 701 million.

The Q4 2025 quarter has no figures in the filed data. Net losses attributable to controlling shareholders over the last four quarters total KRW 167 million.

05

Industry analysis

In cervical cancer cytology screening, liquid-based cytology (LBC) has become the standard approach, which processes cells uniformly before reading. The main products differ in method: ThinPrep is filter-based, BD SurePath is sedimentation-based and Biodyne uses the Blowing method.

First regulatory approvals were ThinPrep in May 1996 (FDA), BD SurePath in June 1999 (FDA), and Biodyne's product in 2009 in Korea. Demand is tied to changes in screening practice, and forecasts point to rising cytology volumes as HPV primary screening and self-sampling become more common.

Because distribution through large in vitro diagnostics companies matters in this market, Roche's position as the world's largest diagnostics business by 2023 revenue affects Biodyne's market access.

With the Roche-branded equipment built on Biodyne's technology now launched, the royalty stream has begun, placing the company in an early commercialization phase. Biodyne relies on Roche's screening network rather than its own sales force, so the pace of expansion tracks the partner's execution.

Compared with large listed companies in the same sector, its revenue base is small, so changes in one or two contract terms carry a large share of earnings. Its strength is usually described as the sensitivity and accuracy of the Blowing technology, a point emphasized in past broker reports.

On the other side, filter-based and sedimentation-based products are already widely installed in laboratories, so switching costs are a variable. Overseas export coverage spans several countries, including Japan, Russia, Portugal and Thailand.

06

Outlook

The growth path depends on how far Roche expands sales of Blowing-technology equipment and kits. Past press reports said the contract renews automatically in five-year periods with no immediate expiry risk, but that statement reflects the time of reporting.

Because royalties are linked to the number of tests performed, cervical screening volumes and the number of installed Roche systems will shape the next revenue trend.

Quarterly revenue in 2026 fell from KRW 867 million in Q1 to KRW 587 million in Q2 before recovering to KRW 701 million in Q3, but operating losses have continued for three quarters, and a return to sustained operating profit is not yet visible in the quarterly data.

The first checkpoint is the FY2026 annual report, which will show how Q4 results feed into the full-year numbers. The key test of whether the FY2025 turnaround reflects recurring royalty earnings is the FY2026 annual operating margin.

Because net losses attributable to controlling shareholders have exceeded operating losses in some quarters, non-operating items and tax lines should be tracked alongside. Another item to watch is whether the overseas distributor share remains above 80% as Roche expands country by country.

Exchange rates matter as well, since the main transaction currencies are the US dollar and the yen. The pace at which cervical screening shifts toward HPV-based programs will also affect demand over the medium to long term.

07

Valuation

PER
—
PBR
3.9×
ROE
-0.4%
EPS
-₩5
BPS
₩1,430
Dividend per share
₩0

The price-to-book ratio places the stock at a premium to book value. With total equity of KRW 44.1 billion at the end of 2025, all of it attributable to controlling shareholders, the gap between the share price and net asset value mainly reflects expectations for royalty income.

The price-to-earnings ratio cannot be calculated because the last four quarters show net losses, which limits earnings-based comparisons for now. Quarterly net losses have continued even after the return to annual operating profit in 2025, so the range of earnings-based interpretation is narrow.

The company paid no cash dividends from 2018 through 2022, and its dividend yield is effectively nil, so dividend-based comparisons are of limited use.

Mid-2024 securities reports built their case for strong earnings growth on the royalty structure, but the 2025 results came in at a smaller scale than those projections.

Market capitalization is far larger than the annual operating profit, which means the enterprise value rests heavily on expectations of royalty income. A useful starting point for reading the valuation is how steadily royalty revenue accumulates in quarterly results.

PER, EPS, PBR and BPS are all calculated in-house (the same method as Naver and Toss) · Dividend yield = cash dividend per share from DART filings (supplemented by KRX) ÷ current price · As of 2026-11-16

08

Bull factors

Royalty structure and partner scale

Because royalties are linked to the number of tests, Roche's expanding equipment and kit sales could push Biodyne's revenue in the same direction. Roche is the world's largest diagnostics business by segment revenue and offers a sales channel that Biodyne could not build alone. The launch of Blowing-based equipment by Roche in 2025 is cited as evidence that commercialization has begun.

FY2025 turnaround and growth

Revenue rose 33.3% to KRW 7.03 billion in 2025, and operating profit moved from loss to KRW 652 million. The operating margin of 9.3% compares with -50.2% in 2023 and -32.8% in 2024. Revenue has grown for two consecutive years from 2024 through 2025, and operating cash flow stayed positive at KRW 830 million in 2025.

Light balance sheet

Total liabilities at the end of 2025 were KRW 871 million, with a debt ratio of 2.0%. Total equity of KRW 44.1 billion is entirely attributable to controlling shareholders, so reliance on external borrowing is small. This financial headroom is cited as a base that could support operations if the royalty stream faces a setback.

09

Bear factors

Operating losses persist through 2026

The company has posted operating losses for three consecutive quarters from Q1 through Q3 2026, with the Q2 loss of KRW 681 million the largest in that span. Q3 revenue of KRW 701 million fell 18.4% from a year earlier.

The most direct bearish point is that the sustainability of the FY2025 turnaround has not yet shown up in quarterly results.

Dependence on a single partner

Growth is concentrated in one partner, Roche. Because supply and royalty values are confidential, the scale of the revenue stream is hard to verify from outside. Roche's launch of its own equipment favors the company, but a change in the partner's sales strategy or priorities could affect revenue directly.

Small revenue base and past one-off income

Annual revenue of about KRW 7 billion is small, so earnings are sensitive to milestone income and exchange rates. More than half of 2022 revenue came from milestone receipts, and revenue fell 66.5% in 2023 when that income disappeared. A repeat of that pattern cannot be ruled out.

10

Risk factors

Partner contract risk

The royalty structure rests on a 20-year contract with Roche that renews automatically. A change in contract terms or in Roche's strategy would affect a large share of revenue. Because the contract values are confidential, the size of this risk is hard to measure from outside.

Quarterly earnings volatility

Q3 2026 revenue rose 19.4% quarter on quarter, yet the operating loss continued and the net loss attributable to controlling shareholders of KRW 1.38 billion was larger than the operating loss. Non-operating items and tax lines have moved differently from quarter to quarter, so the direction of profit often diverges. The Q1 2026 pattern of a positive net profit alongside an operating loss points to the same dynamic.

Export, currency and competition

Overseas distributors account for 80.6% of revenue, so export dependence is high. The main currencies are the US dollar and the yen, so exchange rate moves affect the won value of sales.

Because filter-based ThinPrep and sedimentation-based BD SurePath are widely installed, how far the Blowing method can win conversions is a long-term variable.

11

What to watch next

  1. December 31, 2026

    Fiscal year 2026 ends. Because no Q4 2025 quarterly figure appears in the filed data, how Q4 2026 results feed into the full-year numbers is the point to check.

  2. March 31, 2027 (annual report filing deadline)

    The FY2026 annual report is due. It is the first point to confirm the full-year operating margin and how net profit attributable to controlling shareholders differs from operating results, including the breakdown of non-operating items.

  3. May 15, 2027 (Q1 2027 quarterly report filing deadline)

    The Q1 2027 quarterly report will show whether operating losses extend to a fourth consecutive quarter. The key question is whether royalty revenue from expanded Roche equipment sales is reflected in quarterly results.

12

Overall view

Biodyne's royalty structure is tied to a long-term contract with Roche and linked to the number of tests performed. In 2025 the company moved from loss to KRW 7.03 billion in revenue and KRW 652 million in operating profit, and its debt ratio of 2.0% points to a light financial burden.

On the other side, operating losses have continued for three consecutive quarters from Q1 to Q3 2026, and the net loss attributable to controlling shareholders widened to KRW 1.38 billion in Q3. Growth depends on one partner, and the confidential contract values make its scale hard to gauge from outside.

Because 2022 revenue relied heavily on milestone receipts, whether the business has settled into a repeatable royalty base is the central test. The next checkpoints are the full-year operating margin in the FY2026 annual report and the operating result trend in the Q1 2027 quarterly report.

13

Sources

  1. Korea Exchange (KRX) — Prices · Market Cap · Volume
  2. FSS electronic disclosure system (DART) — Financial statements · Dividend filings
Show 12 more articles and sources
  1. openbizdata.com
  2. pharm.edaily.co.kr
  3. eugenefn.com
  4. thevc.kr
  5. finance.finup.co.kr
  6. asiae.co.kr
  7. dailyinvest.kr
  8. k5.co.kr
  9. app.rndcircle.io
  10. cookiedeal.io
  11. kind.krx.co.kr
  12. m.thinkpool.com

Report written 2026-11-16 · Data as of 2026-11-13

This content is AI analysis of market data and web search results, provided for information only. It is not a solicitation or recommendation to invest. Investment decisions and their consequences are the investor's own responsibility. Data may be delayed or contain errors.

Other reports in this industry

View industry analysis